Home Biosimilar Antibodies Microbiology SARS-CoV Gimsilumab (Anti-CSF2 / GM-CSF)
For research use only. Not for use in humans.

Gimsilumab (Anti-CSF2 / GM-CSF)

Synonyms: CSF2， GM-CSF

Gimsilumab (Anti-CSF2 / GM-CSF) is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the myeloid cell growth factor and inflammatory mediator granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential immunomodulating activity. MW : 145.8 KD.

Gimsilumab (Anti-CSF2 / GM-CSF)

Quality Control

Batch: A285301 Purity: 99% Protein concentration: 6.36mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation SARS-CoV-2 Others
Simnotrelvir 0
Ensitrelvir fumarate 1
GS-621763 0
Bemnifosbuvir Hemisulfate (AT-527) 0
XP-59 0
Coronastat(NK01-63) 0
Paquinimod (ABR-215757) 4
Molnupiravir (EIDD-2801) 15 MERS-CoV
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Gimsilumab (Anti-CSF2 / GM-CSF) is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the myeloid cell growth factor and inflammatory mediator granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential immunomodulating activity. MW : 145.8 KD.
References

Product Details

CAS No. 1648796-29-5
Molecular Weight 145.8
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05232916 RECRUITING Breast Cancer Greenwich LifeSciences, Inc. 2022-12-16 PHASE3
NCT05101356 SUSPENDED Advanced Adenocarcinoma; Advanced Malignant Solid Neoplasm; Metastatic Adenocarcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Adenocarcinoma; Recurrent Malignant Solid Neoplasm University of California, Davis 2021-01-13 PHASE1; PHASE2
NCT06626516 RECRUITING Drug: Tebentafusp-Tebn|Drug: GM-CSF (Sargramostim)|Drug: BCN Metastatic Uveal Melanoma Thomas Jefferson University 2025-10-15 PHASE1; PHASE2
NCT07749365 RECRUITING Drug: hypofractionated radiotherapy plus GM-CSF, pomalidomid DLBCL - Diffuse Large B Cell Lymphoma; PCNSL (Primary CNS Lymphoma) The First Affiliated Hospital of Xiamen University 2026-07-25 PHASE2
NCT07437963 NOT_YET_RECRUITING Drug: Cyclophosphamide|Drug: Iberdomide|Drug: Topotecan Recurrent Ganglioneuroblastoma; Recurrent Neuroblastoma; Refractory Ganglioneuroblastoma; Refractory Neuroblastoma National Cancer Institute (NCI) 2026-10-28 PHASE1; PHASE2
NCT07199413 WITHDRAWN Drug: Cyclophosphamide|Drug: Pembrolizumab|Drug: Interferon Brain Metastases; Leptomeningeal Metastasis Medical College of Wisconsin 2026-06-15 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-08-06)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.